
Amphastar Pharmaceuticals AMPH
€ 19.47
0.17%
Geschäftsbericht 2025
hinzugefügt 26.02.2026
Amphastar Pharmaceuticals Operativer Cashflow 2011-2026 | AMPH
Operativer Cashflow Jährlich Amphastar Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 156 M | 213 M | 184 M | 89.2 M | 98 M | 57.3 M | 41.8 M | 38.2 M | 39.2 M | 38.6 M | 10.7 M | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 213 M | 10.7 M | 87.8 M |
Operativer Cashflow Vierteljährlich Amphastar Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 35.1 M | - | - | - | 55.3 M | - | - | - | 40.4 M | - | - | 53.6 M | 50.8 M | - | - | 55 M | 22.8 M | - | 40.4 M | 31.6 M | 1.48 M | - | 36.1 M | 48.1 M | -3.61 M | - | 28.7 M | 12.9 M | 8.36 M | - | 29.4 M | 27 M | 22.4 M | - | 24.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 55.3 M | -3.61 M | 31 M |
Operativer Cashflow anderer Aktien in der Pharmaeinzelhändler
| Name | Operativer Cashflow | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-12.3 M | $ 5.15 | 15.21 % | $ 12.4 B | ||
|
Allakos
ALLK
|
-116 M | - | - | $ 28.6 M | ||
|
AlloVir
ALVR
|
-38.4 M | - | 4.14 % | $ 49.1 M | ||
|
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M | ||
|
Applied Molecular Transport
AMTI
|
-93.9 M | - | - | $ 10.1 M | ||
|
Applied Therapeutics
APLT
|
-55.2 M | - | - | $ 8.42 M | ||
|
Aptinyx
APTX
|
-59.7 M | - | -39.0 % | $ 4.57 M | ||
|
Genfit SA
GNFT
|
99.9 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M | ||
|
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | ||
|
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | ||
|
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M | ||
|
Aligos Therapeutics
ALGS
|
-82.5 M | $ 6.51 | -2.54 % | $ 64.4 M | ||
|
Avenue Therapeutics
ATXI
|
-1.83 M | - | -52.27 % | $ 4.45 M | ||
|
BioNTech SE
BNTX
|
890 M | $ 105.19 | 2.21 % | $ 27.2 B | ||
|
Aravive
ARAV
|
-65.1 M | - | -13.39 % | $ 1.45 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-8.95 M | $ 3.0 | -1.32 % | $ 4.94 M | ||
|
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M | ||
|
AstraZeneca PLC
AZN
|
5.96 B | - | - | $ 96.9 B | ||
|
AgeX Therapeutics
AGE
|
-18 M | - | -10.17 % | $ 12.2 K | ||
|
Brainstorm Cell Therapeutics
BCLI
|
-6.98 M | - | -2.5 % | $ 5.88 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
68 M | $ 1.43 | 1.78 % | $ 368 M | ||
|
BioDelivery Sciences International
BDSI
|
41 M | - | -4.8 % | $ 255 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-34.5 M | - | - | $ 7.46 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | ||
|
BeiGene, Ltd.
BGNE
|
1.13 B | - | 0.49 % | $ 251 B | ||
|
Aquestive Therapeutics
AQST
|
-52.4 M | $ 4.24 | -1.85 % | $ 453 M | ||
|
Arcutis Biotherapeutics
ARQT
|
-5.62 M | $ 24.47 | -0.24 % | $ 3.11 B | ||
|
Burford Capital Limited
BUR
|
181 M | $ 4.99 | 0.6 % | $ 804 M | ||
|
AIkido Pharma
AIKI
|
22.7 M | - | 1.93 % | $ 17.4 M | ||
|
Autolus Therapeutics plc
AUTL
|
-284 M | $ 1.58 | -1.25 % | $ 420 M | ||
|
Aptose Biosciences
APTO
|
-22 M | - | -45.71 % | $ 1.2 M | ||
|
BioXcel Therapeutics
BTAI
|
-57.6 M | $ 1.2 | 4.35 % | $ 14.6 M | ||
|
AVROBIO
AVRO
|
-63.2 M | - | 1083.1 % | $ 745 M | ||
|
Cabaletta Bio
CABA
|
-131 M | $ 3.31 | -3.92 % | $ 333 M | ||
|
bluebird bio
BLUE
|
-235 M | - | - | $ 546 M | ||
|
Fennec Pharmaceuticals
FENC
|
-12.5 M | $ 6.73 | -0.88 % | $ 192 M | ||
|
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | ||
|
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | ||
|
CymaBay Therapeutics
CBAY
|
-72.5 M | - | - | $ 3.45 B | ||
|
Cidara Therapeutics
CDTX
|
-177 M | - | - | $ 1.41 B | ||
|
ChromaDex Corporation
CDXC
|
13.5 M | - | -0.88 % | $ 598 M | ||
|
Allena Pharmaceuticals
ALNA
|
-45.7 M | - | 3.16 % | $ 1.9 M | ||
|
ContraFect Corporation
CFRX
|
-46 M | - | -5.16 % | $ 5.39 M |